Argus Research has reiterated a ‘Buy’ recommendation for Novo Nordisk (NVO), setting a target price of $140, which indicates a potential upside from its current trading price of $107.

KRChoksey Research has issued a BUY recommendation for Aurobindo Pharma Ltd with a target price (TP) of Rs 1,591, suggesting a 25.6% potential upside from the current market price of Rs 1,267.

Zydus Lifesciences (ZYDUSLIF) has shown resilience in the face of recent stock price corrections and rising competition in the U.S. generics market.

Prabhudas Lilladher has issued an Accumulate rating on Aurobindo Pharma Ltd. (ARBP), setting a target price of Rs 1,475.

Prabhudas Lilladher has reaffirmed its Buy rating on Fortis Healthcare (FORH), setting a revised target price of Rs 710, indicating a potential upside from the current market price of Rs 621.

Prabhudas Lilladher has reaffirmed its Buy rating for Lupin (LPC), raising the target price to Rs 2,420. This revision underscores confidence in Lupin’s strong performance in the U.S.